These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10198233)

  • 1. Molecular design of conjugated tumor necrosis factor-alpha: synthesis and characteristics of polyvinyl pyrrolidone modified tumor necrosis factor-alpha.
    Kamada H; Tsutsumi Y; Tsunoda S; Kihira T; Kaneda Y; Yamamoto Y; Nakagawa S; Horisawa Y; Mayumi T
    Biochem Biophys Res Commun; 1999 Apr; 257(2):448-53. PubMed ID: 10198233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.
    Kamada H; Tsutsumi Y; Yamamoto Y; Kihira T; Kaneda Y; Mu Y; Kodaira H; Tsunoda SI; Nakagawa S; Mayumi T
    Cancer Res; 2000 Nov; 60(22):6416-20. PubMed ID: 11103807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
    Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.
    Tsutsumi Y; Kihira T; Tsunoda S; Kanamori T; Nakagawa S; Mayumi T
    Br J Cancer; 1995 May; 71(5):963-8. PubMed ID: 7734321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.
    Shibata H; Yoshioka Y; Ikemizu S; Kobayashi K; Yamamoto Y; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Hayakawa T; Nagata S; Yamagata Y; Mayumi T; Kamada H; Tsutsumi Y
    Clin Cancer Res; 2004 Dec; 10(24):8293-300. PubMed ID: 15623605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice.
    Kaneda Y; Yamamoto Y; Kamada H; Tsunoda S; Tsutsumi Y; Hirano T; Mayumi T
    Cancer Res; 1998 Jan; 58(2):290-5. PubMed ID: 9443407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.
    Tsunoda S; Ishikawa T; Yamamoto Y; Kamada H; Koizumi K; Matsui J; Tsutsumi Y; Hirano T; Mayumi T
    J Pharmacol Exp Ther; 1999 Jul; 290(1):368-72. PubMed ID: 10381801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of PVP as a polymeric carrier to improve the plasma half-life of drugs.
    Kaneda Y; Tsutsumi Y; Yoshioka Y; Kamada H; Yamamoto Y; Kodaira H; Tsunoda S; Okamoto T; Mukai Y; Shibata H; Nakagawa S; Mayumi T
    Biomaterials; 2004 Jul; 25(16):3259-66. PubMed ID: 14980420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors.
    Tsutsumi Y; Tsunoda S; Kaneda Y; Kamada H; Kihira T; Nakagawa S; Yamamoto Y; Horisawa Y; Mayumi T
    Jpn J Cancer Res; 1996 Oct; 87(10):1078-85. PubMed ID: 8957067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioconjugation of laminin-related peptide YIGSR with polyvinyl pyrrolidone increases its antimetastatic effect due to a longer plasma half-life.
    Mu Y; Kamada H; Kodaira H; Sato K; Tsutsumi Y; Maeda M; Kawasaki K; Nomizu M; Yamada Y; Mayumi T
    Biochem Biophys Res Commun; 1999 Nov; 264(3):763-7. PubMed ID: 10544005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency.
    Tsutsumi Y; Kihira T; Yamamoto S; Kubo K; Nakagawa S; Miyake M; Horisawa Y; Kanamori T; Ikegami H; Mayumi T
    Jpn J Cancer Res; 1994 Jan; 85(1):9-12. PubMed ID: 8106293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous administration of polyethylene glycol-modified tumor necrosis factor-alpha completely regressed solid tumor in Meth-A murine sarcoma model.
    Tsutsumi Y; Kihira T; Tsunoda S; Kubo K; Miyake M; Kanamori T; Nakagawa S; Mayumi T
    Jpn J Cancer Res; 1994 Dec; 85(12):1185-8. PubMed ID: 7852179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
    Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
    Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
    Tsutsumi Y; Tsunoda S; Kamada H; Kihira T; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
    Br J Cancer; 1996 Oct; 74(7):1090-5. PubMed ID: 8855980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular design of polyvinylpyrrolidone-conjugated interleukin-6 for enhancement of in vivo thrombopoietic activity in mice.
    Tsunoda S; Kamada H; Yamamoto Y; Ishikawa T; Matsui J; Koizumi K; Kaneda Y; Tsutsumi Y; Ohsugi Y; Hirano T; Mayumi T
    J Control Release; 2000 Sep; 68(3):335-41. PubMed ID: 10974387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
    Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application.
    Dai C; Fu Y; Chen S; Li B; Yao B; Liu W; Zhu L; Chen N; Chen J; Zhang Q
    Sci China Life Sci; 2013 Jan; 56(1):51-8. PubMed ID: 23314867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective enhancer of tumor vascular permeability for optimization of cancer chemotherapy.
    Yoshioka Y; Tsutsumi Y; Kamada H; Kihira T; Tsunoda S; Yamamoto Y; Okamoto T; Shibata H; Mukai Y; Taniai M; Shimizu T; Kawamura M; Abe Y; Nakagawa S; Mayumi T
    Biol Pharm Bull; 2004 Mar; 27(3):437-9. PubMed ID: 14993819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioconjugation of tumor necrosis factor-alpha with the copolymer of divinyl ether and maleic anhydride increasing its antitumor potency.
    Kaneda Y; Yamamoto Y; Tsunoda S; Kamada H; Tsutsumi Y; Hirano T; Mayumi T
    Biochem Biophys Res Commun; 1997 Oct; 239(1):160-5. PubMed ID: 9345288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma.
    Dai C; Fu Y; Li B; Wang Y; Zhang X; Wang J; Zhang Q
    Sci China Life Sci; 2011 Feb; 54(2):128-38. PubMed ID: 21318482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.